By Maha David, Project Officer - GO
NIH is launching two funding opportunities, PAR-25-110 and PAR-25-111, to support translational and clinical research aimed at advancing precision medicine for pregnant and lactating individuals, as well as children and adolescents, by developing innovative tools and technologies with direct clinical impact. The objective is also to improve understanding of the underlaying drug mechanisms of action, and to promote the discovery and development of therapeutics, including drug repurposing. The overall goal of these two funding opportunities is to improve safe and effective precision therapeutics for pregnant and lactating persons, fetuses, neonates, and children, including those with disabilities. Inter- and multi-disciplinary collaborations are strongly encouraged.
Applications are possible though the NIH R01 and R21 grant mechanisms:
R01 - NIH Research Project Grant: the award budget is not limited but must reflect the actual needs of the project. The maximum project period is 5 years. Four deadlines are available on February 5, June 5 and October 5, 2025, and February 5, 2026.
R21 - NIH Exploratory/Developmental Research Grant Program: the maximum award budget is $275,000 for up to 2 years. Four deadlines are available on February 16, June 16 and October 16, 2025, and February 16, 2026.
Detailed objectives and specific areas of research interest are described in the full notices, R01 and R21, which we encourage you to read entirely.
These funding opportunities align with Priority 4 of the Institut Pasteur's new strategic plan: Health & Diseases at the Extremes of Life - Mother-Child Health
Don’t hesitate to reach out to us if you are interested at gointernational[at]pasteur.fr. We will be delighted to help you understand NIH expectations and prepare your application.
Comments